Literature DB >> 28943896

A large Chinese pedigree of multiple endocrine neoplasia type 2A with a novel C634Y/D707E germline mutation in RET exon 11.

Fanqian Lu1,2, Xiaohong Chen1,2, Yunlong Bai1,2, Yaru Feng1,2, Jian Wu3.   

Abstract

The present study identified the clinical features of the largest multiple endocrine neoplasia type 2 (MEN2) A pedigree from China, with a novel double missense rearranged during transfection (RET) mutation (C634Y/D707E). To the best of our knowledge, the D707E mutation has not been identified to date. In the present study, a total of 101 family members who originated from a large pedigree (134 members in total) underwent RET mutation screening by next-generation sequencing and polymerase chain reaction (PCR) amplification, followed by direct bidirectional DNA sequencing. The clinical features of this pedigree were carefully reviewed retrospectively, and statistical analyses were conducted using SPSS software. A total of 33 (32.67%) carriers were identified to exhibit the C634Y/D707E RET germline mutation. The mean age of the patients with medullary thyroid carcinoma (MTC) identified by RET screening was 38.4±16.5 years (n=11; range, 14-65 years). Only 4 patients with pheochromocytoma with a median age of 37 years were identified. No hyperparathyroidism was diagnosed. Persistent or recurrent disease developed in the patients of the present study who underwent inappropriate initial thyroid surgeries that were performed in previous decades (III10, III23, III24, III27 and IV46, as they had undergone two surgeries prior to the present study). A total of 66.70% (6/9) of patients, following thyroidectomy, continued to develop persistent or recurrent disease during the present screening study. In total, 3 patients succumbed to MTC or distant metastasis in the present study. The increase in carcinoembryonic antigen (CEA) levels correlated with the increase in basal serum calcitonin (Ct) levels according to Pearson correlation analysis in patients with MTC without surgery. Ct and CEA levels were also significantly correlated with tumor volumes. To the best of our knowledge, the present study is the first to identify a novel double RET missense mutation in the largest MEN2A pedigree from China. Additional in-depth study is necessary to elucidate the molecular mechanisms of the D707E mutation and its potential joint effects with the other C634Y mutation in the pedigree of the present study.

Entities:  

Keywords:  C634Y; D707E; MEN2A; double mutation; medullary thyroid carcinoma

Year:  2017        PMID: 28943896      PMCID: PMC5592869          DOI: 10.3892/ol.2017.6583

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  26 in total

1.  Sporadic versus familial medullary thyroid microcarcinoma: a histopathologic study of 50 consecutive patients.

Authors:  K Kaserer; C Scheuba; N Neuhold; A Weinhäusel; O A Haas; H Vierhapper; B Niederle
Journal:  Am J Surg Pathol       Date:  2001-10       Impact factor: 6.394

2.  Abnormal carcinoembryonic antigen levels and medullary thyroid cancer progression: a multivariate analysis.

Authors:  Andreas Machens; Jörg Ukkat; Steffen Hauptmann; Henning Dralle
Journal:  Arch Surg       Date:  2007-03

Review 3.  CEA-related antigens: molecular biology and clinical significance.

Authors:  J E Shively; J D Beatty
Journal:  Crit Rev Oncol Hematol       Date:  1985       Impact factor: 6.312

Review 4.  Guidelines for diagnosis and therapy of MEN type 1 and type 2.

Authors:  M L Brandi; R F Gagel; A Angeli; J P Bilezikian; P Beck-Peccoz; C Bordi; B Conte-Devolx; A Falchetti; R G Gheri; A Libroia; C J Lips; G Lombardi; M Mannelli; F Pacini; B A Ponder; F Raue; B Skogseid; G Tamburrano; R V Thakker; N W Thompson; P Tomassetti; F Tonelli; S A Wells; S J Marx
Journal:  J Clin Endocrinol Metab       Date:  2001-12       Impact factor: 5.958

5.  High penetrance of pheochromocytoma in multiple endocrine neoplasia 2 caused by germ line RET codon 634 mutation in Japanese patients.

Authors:  Tsuneo Imai; Shinya Uchino; Takahiro Okamoto; Shinichi Suzuki; Shinji Kosugi; Toyone Kikumori; Akihiro Sakurai
Journal:  Eur J Endocrinol       Date:  2013-04-15       Impact factor: 6.664

Review 6.  Medullary thyroid cancer diagnosis: an appraisal.

Authors:  Pierpaolo Trimboli; Luca Giovanella; Anna Crescenzi; Francesco Romanelli; Stefano Valabrega; Giuseppe Spriano; Nadia Cremonini; Rinaldo Guglielmi; Enrico Papini
Journal:  Head Neck       Date:  2014-03-04       Impact factor: 3.147

7.  A two-hit model for development of multiple endocrine neoplasia type 2B by RET mutations.

Authors:  T Iwashita; H Murakami; K Kurokawa; K Kawai; A Miyauchi; H Futami; S Qiao; M Ichihara; M Takahashi
Journal:  Biochem Biophys Res Commun       Date:  2000-02-24       Impact factor: 3.575

8.  High penetrance of pheochromocytoma associated with the novel C634Y/Y791F double germline mutation in the RET protooncogene.

Authors:  Rodrigo A Toledo; Simona M Wagner; Flavia L Coutinho; Delmar M Lourenço; Juliana A Azevedo; Viviane C Longuini; Mariana T A Reis; Sheila A C Siqueira; Antonio M Lucon; Marcos R Tavares; Maria C B V Fragoso; Adelaide A Pereira; Patricia L M Dahia; Lois M Mulligan; Sergio P A Toledo
Journal:  J Clin Endocrinol Metab       Date:  2010-01-15       Impact factor: 5.958

9.  Current management of medullary thyroid cancer.

Authors:  Rebecca S Sippel; Muthusamy Kunnimalaiyaan; Herbert Chen
Journal:  Oncologist       Date:  2008-05

10.  Factors predicting outcome of total thyroidectomy in young patients with multiple endocrine neoplasia type 2: a nationwide long-term follow-up study.

Authors:  Jennifer M J Schreinemakers; Menno R Vriens; Gerlof D Valk; Jan-Willem B de Groot; John T Plukker; Klaas M A Bax; Jaap F Hamming; Rob B van der Luijt; Daniel C Aronson; Inne H M Borel Rinkes
Journal:  World J Surg       Date:  2010-04       Impact factor: 3.352

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.